Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03784924 · ClinicalTrials.gov registry record
EDRN Prostate MRI Biomarker Study
A clinical trial of Prostate Cancer and PSA, sponsored by University of Michigan.
- Recruiting
- Registry status
- 950
- Enrollment target
- 1
- Study location
NCT03784924 is a study of Prostate Cancer and PSA that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 950 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (57% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03784924, a study of Prostate Cancer and PSA, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- 950 participants
- Enrollment target
- 1
- Study location
Study Summary
The commercialization of MRI fusion biopsies has resulted in a dramatic increase in the use of MRI imaging for prostate cancer. How best to use MRI in the initial prostate biopsy setting given the availability of validated prostate cancer early detection markers is uncertain.This study will allow investigators to determine if prostate MRI is superior to validated panel of laboratory biomarkers (e.g. PCA3, PSA and TMPRSS2:ERG) in the initial biopsy setting.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST MRI prostate
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 950 participants |
| Start Date | 2019-02-04 |
| Est. Completion | 2028-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03784924
The ClinicalTrials.gov registry entry for NCT03784924 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 950 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (57% higher). The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which MRI prostate is the first listed.
NCT03784924 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT03784924 about?
NCT03784924 is a clinical study titled "EDRN Prostate MRI Biomarker Study". The commercialization of MRI fusion biopsies has resulted in a dramatic increase in the use of MRI imaging for prostate cancer. How best to use MRI in the initial prostate biopsy setting given the availability of validated prostate cancer early detection markers is uncertain.This study will allow in...
What is the current status of trial NCT03784924?
This trial is currently recruiting. The enrollment target is 950 participants. The study started on 2019-02-04. Estimated completion is 2028-12-31.
What conditions does trial NCT03784924 study?
This clinical trial studies the following conditions: Prostate Cancer, PSA.
What interventions are being tested in trial NCT03784924?
The interventions under investigation include: MRI prostate (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03784924?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03784924 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.